The pharmaceutical industry is known to generate substantial profits due to its pricing strategies. These strategies involve setting high prices for medications, often resulting in financial burdens for patients. The industry justifies these prices by citing research and development costs, as well as the need to fund future innovation. However, critics argue that this approach prioritizes profit over patient accessibility and affordability. The debate surrounding pharmaceutical pricing is complex and multifaceted, with various stakeholders advocating for reforms and increased transparency. In recent years, the issue has gained significant public attention, spurring discussions on the need for regulatory measures to ensure a fair balance between profits and patient welfare.